Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib-based induction/consolidation or prolonged therapy with lenalidomide-based maintenance in transplant-eligible newly diagnosed multiple myeloma
2014-000782-53Phase 2Active
- Sponsor
- University of Turin
- Start
- Oct 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carfilzomib, cyclophosphamide, lenalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by University of Turin. Primary endpoint: Very good partial response rate after induction. Started Oct 2014; status: active.
02
Drugs
carfilzomibcyclophosphamidelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-000782-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000782-53.